Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors

BACKGROUND: Management of triple-negative breast cancer (TNBC) is still challenging because of its aggressive clinical behavior and limited targeted treatment options. Cisplatin represents a promising chemotherapeutic compound in neoadjuvant approaches and in the metastatic setting, but its use is l...

Descripción completa

Detalles Bibliográficos
Autores principales: Agnello, Lisa, Tortorella, Silvia, d’Argenio, Annachiara, Carbone, Clarissa, Camorani, Simona, Locatelli, Erica, Auletta, Luigi, Sorrentino, Domenico, Fedele, Monica, Zannetti, Antonella, Franchini, Mauro Comes, Cerchia, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299618/
https://www.ncbi.nlm.nih.gov/pubmed/34294133
http://dx.doi.org/10.1186/s13046-021-02039-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299618/
https://www.ncbi.nlm.nih.gov/pubmed/34294133
http://dx.doi.org/10.1186/s13046-021-02039-w

Ejemplares similares